Scientists put bowel cancer under the microscope

May 24, 2013
Researcher Soozana Puvanenthira in the laboratories at London's Kingston University.

Researchers from London's Kingston University have begun a two-year study which could help prolong the lives of people with colorectal tumours.

Patients with – the third most commonly diagnosed form in the United Kingdom – could enjoy increased as a result of a new study led by an expert from London's Kingston University. Professor Helmout Modjtahedi is heading an investigation examining why some tumours are hard to treat and how they can be targeted with the most effective therapies.

During the study, specimens from patients with tumours of the colon or , known as colorectal or bowel , will be examined for biomarkers – proteins on the surface of cells. This would help pinpoint which individuals were most likely to benefit from specific therapies, particularly two new antibody-based drugs, Professor Modjtahedi said. Since the drugs cost tens of thousands of pounds a year, targeting their use would help reduce costs, while patients who would not benefit from them could be spared the trauma of unnecessary treatment and offered an alternative instead.

The researchers are aiming to develop a to demonstrate which patients would respond to specific treatments by the end of the study. "This is something that will have a huge impact, not just for colorectal cancer sufferers, but also for people with other forms such as lung, breast, head or ," Professor Modjtahedi said. "This is because these patients may also be treated with or small targeted at the under investigation. We hope our far-reaching work will improve patients' lives as well as helping health authorities direct their resources where they are most needed. We anticipate it will play a significant role in the response, survival and cure rates for patients."

The two-year study, due to conclude in April 2015, has attracted £107,000 in funding from cancer charity BRIGHT (Better Research into Gastrointestinal Cancer Health and Treatment), based at St Luke's Cancer Centre at the Royal Surrey County Hospital in Guildford.

Colorectal cancer is hard to treat in the majority of cases. People diagnosed at an early stage have a good survival rate – 90 per cent after five years – but this figure drops to 68 per cent for those detected at an advanced stage and just 10 per cent when it has spread to other parts of the body. In the United Kingdom it is the second most commonly diagnosed cancer in women and the third in men – responsible for around 19,000 deaths a year.

Professor Modjtahedi has been a specialist in cancer biology at Kingston University since 2007 and has amassed more than 20 years' experience researching in the field. His most recently-completed study in the laboratories at Kingston University, also funded by BRIGHT, found that some colorectal cancers had more than one marker and therefore needed more than one drug or combination of drugs to treat them. That three-year probe also looked at the reasons patients sometimes responded to treatment in the early stages only to suffer setbacks when the drugs subsequently stopped working.

The current study will explore in more detail why some patients' cancers develop a resistance to treatment and how this can be overcome using different combinations of drugs. It will also aim to identify some of the biomarkers that will allow doctors to select which drugs will benefit which patients.

The biomarkers Professor Modjtahedi and his team are focusing their attention on come from a family known as epidermal growth factor receptors (EGFR). In patients with a high level of EGFR, cancer cells can divide more rapidly – escalating the disease and making it harder to treat. The team has already developed antibodies capable of blocking the actions of EGFR and detecting such proteins in specimens from patients.

The preliminary findings of Professor Modjtahedi's research have been published in the British Journal of Cancer.

Explore further: Genetic mutations found linked to rare cases of multiple bowel tumors

Related Stories

Genetic mutations found linked to rare cases of multiple bowel tumors

July 5, 2016
Researchers have identified genetic mutations affecting the immune system which may lead to the development of more than one bowel tumour at the same time. Understanding how these cancers develop could improve targeting of ...

Study opens door to targeted treatments for esophageal cancer

September 5, 2016
Scientists have discovered that oesophageal cancer can be classified into three different subtypes, paving the way for testing targeted treatments tailored to patients' disease for the first time.

Imaging technique could help focus breast cancer treatment

July 8, 2016
Cancer Research UK scientists have used imaging techniques as a new way to identify patients who could benefit from certain breast cancer treatments, according to a study published in Oncotarget.

New test could help select the best treatment for bowel cancer patients

February 11, 2016
A new test could help patients with advanced bowel cancer get the best treatment for their disease, according to a Cancer Research UK clinical trial published today in JAMA Oncology.

Helping to stop colorectal cancer by identifying metastasis chances early

March 15, 2016
Colorectal cancer, one of the most commonly diagnosed cancers in the United States, is not a commonly discussed disease. Often symptomless in early stages, the cancer is more difficult to treat as it progresses, requiring ...

Survival three times higher when cancer is diagnosed early

August 10, 2015
Survival for some of the most common types of cancer is more than three times higher when the disease is diagnosed in the earlier stages, according to new figures published by Cancer Research UK.

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.